Understanding Your Diagnosis: ADAR-Related Hereditary Spastic Paraplegia

Receiving a diagnosis of ADAR-related Hereditary Spastic Paraplegia (HSP) can feel like entering a world of medical complexity. This condition is part of a larger family of rare genetic disorders caused by changes in the ADAR1 gene ^[1]. Because it is so rare, you may find that many people—including some healthcare providers—are unfamiliar with it. This page is designed to help you navigate these early days by explaining what the research says, where the uncertainties lie, and how this diagnosis fits into your life.

Understanding the Rarity

If you feel like you have been handed a diagnosis that is hard to find information on, you are right. While Hereditary Spastic Paraplegia (HSP) as a group affects roughly 1 to 10 people out of every 100,000, ADAR-related HSP is a very specific and much rarer subtype ^[2]. Currently, there is no exact “incidence rate” (how many new cases appear each year) for this specific genetic form because it is so infrequently diagnosed ^[3].

Most of what we know comes from small groups of patients and individual case studies rather than large population-wide research ^[4]. This rarity means your medical team may still be learning about your specific presentation, and your journey will be unique to you.

The ADAR1 Disease Spectrum

The ADAR1 gene is responsible for making a protein that helps the body tell the difference between its own genetic material and invading viruses ^[5]. When this gene doesn’t work correctly, the immune system can become overactive, leading to inflammation ^[6]. Because this gene is so fundamental, changes in it can cause a wide range of symptoms, which doctors refer to as a disease spectrum ^[7].

• Isolated Spastic Paraplegia: This is a presentation where the primary symptom is stiffness and weakness in the legs (spasticity) ^[8].
• Aicardi-Goutières Syndrome Type 6 (AGS6): This is a more complex form that often starts in infancy. It can involve brain inflammation, developmental delays, and sometimes seizures or calcium deposits in the brain ^[9].
• Dyschromatosis Symmetrica Hereditaria (DSH): This form primarily affects the skin, causing a mix of light and dark spots on the hands and feet ^[10].

It is important to understand that these categories are not always “neat.” Some people may have symptoms that overlap between these conditions, such as having the leg stiffness of HSP along with the skin spots of DSH ^[9].

What This Diagnosis Means for You

A diagnosis of ADAR-related HSP typically means the nervous system—and sometimes the immune system—is functioning differently than expected.

• Movement: The most common feature is spasticity, which is a type of muscle stiffness that makes movement, particularly walking, more difficult ^[11]. Some patients may also experience dystonia, which causes involuntary muscle contractions or twisting ^[1].
• Immune Function: Because the ADAR1 gene helps regulate the immune system, your body may produce too much of a protein called interferon ^[5]. While this doesn’t always cause visible symptoms, doctors sometimes monitor it through blood tests to see how active the disease is ^[8].
• Variability: One of the most important things to know is that the genetic code does not always predict exactly how someone will feel. Even members of the same family with the same genetic variant can have very different symptoms and levels of severity ^[12][8]. An unaffected relative may be an unaffected carrier in a recessive family, or may have reduced expression of a dominant variant, meaning recurrence risks vary. A genetic counselor can help guide phase testing and cascade testing.

Navigating the Uncertainty

It is natural to fear the unknown, especially regarding whether symptoms will get worse. Research shows that while some forms of ADAR-related disease can be progressive (meaning they change over time), this is not true for everyone ^[1]. In a review of 57 patients with mixed ADAR-related conditions, about 43% had a progressive course, but this included the most severe types of the disease; it is not a direct prediction for an individual with “pure” HSP, and referral bias is likely ^[1].

Current research is still trying to answer key questions, such as:

• Why do some people with the gene change show no symptoms while others are more affected (incomplete penetrance) ^[8]?
• How can we best use “immune-modulating” drugs to help manage the condition ^[8]?
• What are the best long-term ways to support mobility and quality of life ^[13]?

Your diagnosis is the start of a conversation, not a final answer. By working with a team that understands both the neurological and immunological sides of this condition, you can focus on managing symptoms and maintaining function for the long term ^[14].